Home > Insider Trading > Filing (0000950170-23-048440)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701108	Spero Therapeutics Inc.	SPRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1946366	Kamal Hamed	C/O Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14Th Floor Cambridge MA 02139	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-09-13	39,496	$1.27	576,461	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of (i) restricted stock units ("RSUs") that were granted to the Reporting Person on September 12, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement and (ii) performance-based restricted stock units ("PSUs") that were granted to the Reporting Person on August 4, 2022, subject to the achievement of certain pre-established performance criteria, which the Board of Directors of the Issuer determined had been 100% met on June 12, 2023, pursuant to a "sell to cover" provision included in the PSU Agreement.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.